Be Prepared to Treat Scurvy in Critically Ill Patients with ASCOR®

  • Despite receiving standard ICU nutritional support, as many as 1/3 of critically ill patients may have ascorbic acid levels low enough to be scorbutic 1
  • A study reports that 22% of patients with community-acquired pneumonia had Vitamin C deficiency (defined as plasma Vitamin C level less than 11 ┬Ámol/L.) 2
  • Critically ill patients are at increased risk for Vitamin C depletion due to inflammation and increased metabolic consumption caused by oxidative stress and increased reactive oxygen species production 1
  • In addition to increased metabolic consumption of Vitamin C in critical illness, absorption of Vitamin C may also be negatively impacted. For example, patients with severe sepsis experience an explosive cytokine release which interferes with the cellular regulation of Vitamin C absorption. 3

If your critically ill patients who are unable to take oral Vitamin C show signs and symptoms of scurvy, prescribe ASCOR®, the only FDA-approved ascorbic acid injection.

Click here to learn more about the signs and symptoms of scurvy
  1. Carr, A. et. Al. Critical Care 2017; 21: 300. Hypovitaminosis C and vitamin C deficiency in critically ill patients despite recommended enteral and parenteral intakes - PubMed (
  2. Carr A.C., et al. Patients with Community-Acquired Pneumonia Exhibit Depleted Vitamin C Status and Elevated Oxidative Stress. Nutrients. 2020; 12: 1318.
  3. Kashiouris, M, et al. The Emerging Role of Vitamin C as a Treatment for Sepsis. Nutrients. 2020; 12: 292.

Indication & Important Safety Information

ASCOR® is vitamin C indicated for the short term (up to 1 week) treatment of scurvy in adult and pediatric patients age 5 months and older for whom oral administration is not possible, insufficient or contraindicated.

Limitations of Use:
ASCOR® is not indicated for treatment of vitamin C deficiency that is not associated with signs and symptoms of scurvy.

Important Safety Information

Contraindications: None.

Administration site reactions include pain and swelling.

ASCOR® should not be rapidly administered. Rapid intravenous administration (>250 mg/minute) of ASCOR® may cause temporary faintness or nausea, lethargy, flushing, dizziness, and headache.

Acute and chronic oxalate nephropathy have occurred with prolonged administration of high doses of ascorbic acid. ASCOR® is not indicated for prolonged administration. The maximum recommended duration is one week.

In patients with glucose-6-phosphate dehydrogenase deficiency severe hemolysis has occurred.

Ascorbic acid may interfere with laboratory tests based on oxidation-reduction reactions, including blood and urine glucose testing, nitrite and bilirubin levels, and leucocyte count testing. If possible, laboratory tests based on oxidation-reduction reactions should be delayed until 24 hours after infusion of ASCOR®.

Please see accompanying Full Prescribing Information for ASCOR®.


The information contained in this section of the site is intended for U.S. healthcare professionals only.